For a story about sweethearts and heartache, it's a pity that you will likely forget Love In Vietnam in a heartbeat, notes Mayur Sanap.
Ask rediffGURU Naveenn Kummar your insurance mutual fund and personal finance-related questions.
Ghaati does not understand how to harness Anushka Shetty's electrifying screen presence, complains Arjun Menon.
Inspector Zende had the potential to be genuinely entertaining. Instead, it settles for formulaic fun, observes Mayur Sanap.
If the 'Captain Cool' trademark goes through, it could trigger a wave of similar attempts by celebrities to trademark nicknames given to them by fans.
'No one anticipated magical solutions or miraculous interventions.' 'However, people across the entire spectrum -- whether residing in the valley or the hills -- expected the prime minister to dedicate at least five to ten minutes to genuinely listening to the voice of the people.'
The Delhi High Court has restrained Patanjali from running disparaging advertisements against Dabur Chyawanprash, following a plea by Dabur alleging that Patanjali's ads were disparaging their product and Chyawanprash in general.
US accounts for a large part of revenue for top Indian pharma companies like Gland Pharma (54 percent), Dr Reddy's (53 per cent), and Aurobindo Pharma (48 per cent).
India has not accepted the demand of the UK for inclusion of a 'data exclusivity' provision in the free trade agreement, announced on May 6, in a bid to protect the interests of the domestic generic drugs industry, an official said. During the negotiations, the UK had asked to include this provision in the trade pact.
All doctors must prescribe generic drugs, failing which they will be penalised and even their license to practice may also be suspended for a period, according to the new regulations issued by the National Medical Commission (NMC).
Rising penetration of trade generic medicines is eating into the value growth of the domestic pharmaceutical market, showed a recent analysis. According to a Kotak Institutional Equities analysis, 70-110 basis points (bps) annual dent is expected from trade generics and Jan Aushadhi on Indian Pharma Market (IPM) growth at least until FY27-28 (see chart). Trade generic medicines are those that are not pushed into the market through doctor promotions.
The restructuring of tariffs by the US has led to a shift in the list of key product suppliers to the American market, with India emerging as one of the beneficiaries at the expense of China and Canada, an official said on Monday. As per an analysis, India's share in the USA's electronics exports has increased to 7.2 per cent to 3.5 per cent year-on-year in May, while China's share dipped to 11 per cent from 22 per cent during the same period.
US President Donald Trump's plan to sign an executive order to cut prescription drug prices by 30-80 per cent could lead to a global price adjustment with pharma firms pushing lower-cost countries like India to raise prices, according to the economic think tank GTRI. The US move could push prices in lower-cost countries like India as manufacturers would seek to recover losses and R&D costs from these nations.
At the end of the day, this isn't about choosing between EMIs and SIPs. It's about choosing your path to financial freedom.
What keeps the momentum going is Kajol's fully committed performance that elevates this generic material to a surprising degree of watchability, feels Mayur Sanap.
'What India has done will surely embolden more countries to stand up to Trump.'
While most investors brush off NFOs like spam, some of them offer solid opportunities, especially when you know what to look for. So let's clear the confusion around NFOs and figure out when they're worth your money, and when they're not.
It looks like Diljit is having a field day with this one, one hopes his joy rubs off on viewers as well, notes Mayur Sanap.
India and the UK on Thursday inked a landmark free trade agreement (FTA) that will cut tariffs on British whisky, cars and an array of items, besides boosting bilateral trade by around $34 billion annually.
Ask rediffGURU and PF and MF expert Janak Patel your mutual fund and personal finance-related questions.
Despite a healthy performance in the fourth quarter of 2024-25 (Q4FY25), the stock of India's largest listed pharma company, Sun Pharmaceutical Industries (Sun Pharma), was under pressure on Friday due to a muted guidance. The company has guided for a high single-digit revenue growth for FY26, which is below what the Street was working with.
Chhal Kapat is a bland whodunnit, which does not have the necessary skills and smarts to pull it off, notes Mayur Sanap.
Indian drugmakers supply 47 per cent of the generic medicine requirements in the US, and tariffs would have increased prices in the US domestic market for patients, who are already dealing with drug shortages.
The current situation in Kerala politics is perhaps best described as a case of the state's traditional two front politics now seeing a third front (the BJP) muscling in with the potential outcome being either a messy three front affair or a renewed endorsement of the two front pattern but with one of the old fronts compromised or quashed, observes Shyam G Menon.
India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 crore anti-diabetic drug market in India is growing at 9 per cent or so.
Pharma major Dr Reddy's Laboratories delivered a muted operational performance in the fourth quarter of financial year 2024-25 (Q4FY25), even as revenue growth remained healthy. Lower gross margin performance and muted domestic growth are key concerns. Most brokerages have a "Sell" or "Reduce" rating as there are uncertainties related to the development of a new product portfolio and the launch timelines.
The two immensely watchable stars aside, War 2 looks like a banal amalgam of every action flick we have seen before.
After falling 17 per cent since the start of the year to its March lows, the stock of the country's largest pharmaceutical (pharma) company, Sun Pharmaceutical Industries, has clawed back nearly half of those losses. Recent acquisitions, a favourable court ruling in the case of the hair loss drug Leqselvi, an edge over peers owing to its specialty portfolio, and a diversified global presence have supported the recovery.
Infosys has laid off 195 trainees for failing internal assessments, according to emails sent by India's second largest IT services firm. It is the company's third layoff of trainees this year. As many as 320 trainees were dropped in February on similar grounds and 240 earlier this month.
Trade generic drugs (medicines that are sold directly through distributors) are fast becoming a key segment for domestic pharma firms as volume growth slows in the overall market. Big companies like Cipla and Alkem have a significant presence in the segment but recently, players like Torrent Pharmaceuticals and Dr Reddy's Laboratories (DRL) have also entered this market. What is driving big pharma's focus on trade generics? The volume growth in the Indian Pharma Market (IPM) has come down from 5.6 per cent in FY16 to 0.1 per cent in FY23.
Gill's first X post of the IPL 2025 season, following Gujarat Titans' victory over Royal Challengers Bengaluru, sparked intense speculation.
'That combination of a rising economy, a growing middle class, and a deepening love of diamonds and jewellery is what we see really doubling the market for diamonds over the next five years.'
'Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.'
The contrast between Iyer's selflessness and Kohli's perceived self-interest fuelled online discussions, with many interpreting Shastri's comment as a veiled critique of Kohli's actions.
The BSE Healthcare Index is up 19 per cent as compared to BSE Sensex returns of 11 per cent during this period. Nitin Agarwal of DAM Capital highlighted this trend in a report last month. "After a sustained period of underperformance over FY21-23, the BSE Healthcare Index has once again captured the spotlight. "The recent uptick in performance has been driven by hospitals and emerging green shoots in pharmaceutical exports, particularly to the US, along with sustaining momentum in domestic branded formulations," he said.
The Securities and Exchange Board of India (Sebi), in a circular dated April 11, 2025, warned investors about rising fraud and manipulation linked to the securities market on social media platforms.
Over the years, with some amount of experimenting, I have learnt exactly what freezes well and what does not.
Members of the IMA and IPA had met Mansukh Mandaviya on Monday and expressed their concerns over the regulations.
Indian pharmaceutical companies may have units abroad as part of "distributed manufacturing" across various locations, according to industry veterans. This may come about over the next five to 10 years.
Call centres, once the engine room of India's BPO exports, are evolving too. Depending on the complexity, 30 to 50 per cent of voice and chat volumes are now handled by conversational AI.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances